Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: Bayer plc, 400 South Oak Way, Reading, RG2 6AD
Nimotop 30mg Tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Yellow, round biconvex tablets with “SK” marked on one side and the Bayer cross marked on the other side. |
Each film-coated tablet contains 30 mg nimodipine.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Nimodipine |
Nimodipine is a dihydropyridine calcium channel blocker with particular cerebrovascular effect. Nimodipine increases cerebral perfusion, particularly in poorly perfused areas, by arterial dilatation, an effect which is proportionately greater in smaller than in larger vessels. |
| List of Excipients |
|---|
|
Microcrystalline cellulose |
PP/aluminium blister packs contained in cardboard outer, containing 100 × 30mg tablets.
Bayer plc, 400 South Oak Way, Reading, RG2 6AD
PL 00010/0137
23 February 1989/23 November 2003
| Drug | Countries | |
|---|---|---|
| NIMOTOP | Austria, Canada, Cyprus, Germany, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Malta, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
